Self-reported oral dryness and hiv disease in a national sample of patients receiving medical care

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 92, Issue 6, 2001, Pages 629-636

  Younai, Fariba S ^a,c   Marcus, Marvin ^a   Freed, James R ^a   Coulter, Ian D ^a,b   Cunningham, William ^a   Der Martirosian, Claudia ^a   Guzman Bercerra, Norma ^a   Shapiro, Martin ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RAND CORPORATION   (United States)

^c UCLA SCHOOL OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; IMMUNOLOGICAL ADJUVANT; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ARTICLE; COHORT ANALYSIS; ETHNIC GROUP; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MALE; RISK; SELF EVALUATION; SMOKING; STATISTICAL MODEL; UNITED STATES; VIRUS LOAD; XEROSTOMIA;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; ANTITUBERCULAR AGENTS; CD4-CD8 RATIO; COHORT STUDIES; FEMALE; HISPANIC AMERICANS; HIV INFECTIONS; HUMAN; LOGISTIC MODELS; MALE; MIDDLE AGE; ODDS RATIO; SELF ASSESSMENT (PSYCHOLOGY); SMOKING; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; UNITED STATES; VIRAL LOAD; XEROSTOMIA;

EID: 0035651453     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1067/moe.2001.117816     Document Type: Article

References (31)

1. Schiødt M, Dodd CL, Greenspan D, Daniels TE, Chemoff D, Hollander H, et al. Natural history of HIV-associated salivary gland disease. Oral Surg Oral Med Oral Pathol 1992;74:326-31.
2. Pahwa S, Fikrig S, Kaplan M, Kahn E, Pahwa R. Expressions of HTLV-III infection in a pediatric population. Adv Exp Med Biol 1985;187:45-51.
3. Schiødt M, Pindborg JJ. AIDS and the oral cavity. Epidemiology and clinical oral manifestations of human immune deficiency virus infection: a review. Int J Oral Maxillofac Surg 1987;16:1-14.
4. Silverman S Jr, Migliorati CA, Lozada-Nur F, Greenspan D, Conant MA. Oral findings in people with or at risk for AIDS: a study of 375 homosexual males. J Am Dent Assoc 1986;112:187-92.
5. Kordossis T, Paikos S, Aroni K, Kitsanta P, Dimitrakopoulos A, Kavouklis E, et al. Prevalence of Sjøgren's-like syndrome in a cohort of HIV-1-positive patients: descriptive pathology and immunopathology. Br J Rheumatol 1998;37:691-5.
6. Mandel L, Kim D, Uy C. Parotid gland swelling in HIV diffuse infiltrative CD8 lymphocytosis syndrome. Oral Surg Oral Med Oral Pathol Radiol Endod 1998;85:565-8.
7. Huang RD, Pearlman S, Friedman WH, Loree T. Benign cystic vs. solid lesions of the parotid gland in HIV patients. Head Neck 1991;13:522-7.
8. Itescu S, Brancato LJ, Buxbaum J, Gregersen PK, Rizk CC, Croxson TS, et al. A diffuse infiltrative CD8 lymphocytosis syndrome in human immunodeficiency virus (HIV) infection: a host immune response associated with HLA-DR5. Ann Intern Med 1990;112:3-10.
9. Greenberg MS, Glick M, Nghiem L, Stewart JC, Hodinka R, Dubin G. Relationship of cytomegalovirus to salivary gland dysfunction in HIV-infected patients. Oral Surg Oral Med Oral Pathol Radiol Endod 1997;83:334-9.
10. Itescu S, Mathur-Wagh U, Skovron ML, Brancato LJ, Marmor M, Zeleniuch-Jacquotte A, et al. HLA-B35 is associated with accelerated progression to AIDS. J Acquir Immune Defic Syndr 1992;5:37-45.
11. Von Bargen J, Moorman Anne, Holmberg S. How many pills do patients with HIV infection take [letter]? JAMA 1998;280:29.
12. Valentine C, Deenmamode J, Sherwood R. Xerostomia associated with didanosine. Lancet 1992;340:1542-3.
13. Dodd CL, Greenspan D, Westenhouse JL, Katz MH. Xerostomia associated with didanosine [letter]. Lancet 1992;340:790.
14. The Alpha trial: European/Australian randomised double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. Alpha International Coordinating Committee. AIDS 1996;10:867-80.
15. Thompson WM, Chalmers JM, Spencer AJ, Slade GD. Medication and dry mouth: findings from a cohort study of older people. J Public Health Dent 2000;60:12-20.
16. Shapiro MF, Berk ML, Berry SH, Emmons CA, Athey LA, Hsia DC, et al. National probability samples in studies of low-prevalence diseases. Part I: perspectives and lessons from the HIV cost and services utilization study. Health Serv Res 1999;34:951-68.
17. Frankel MR, Shapiro MF, Duan N, Morton SC, Berry SH, Brown JA, et al. National probability samples in studies of low-prevalence diseases. Part II: designing and implementing the HIV Cost and Services Utilization Study. Health Serv Res 1999;34:969-92.
18. Bozzette SA, Berry SH, Duan N, Frankel MR, Leibowitz AA, Lefkowitz D, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med 1998;339:1897-904.
19. Fox P, van der Ven PF, Sonies BC, Weiffenbach JM, Baum BJ. Xerostomia: evaluation of a symptom with increasing significance. J Am Dent Assoc 1985;110:519-25.
20. Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr. Changing prevalence of oral manifestations of human immunodeficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;89:299-304.
21. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995;96:456-64.
22. Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci U S A 1986;83:6692-6.
23. Müller F, Frøland SS, Hvatum M, Radl J, Brandtzaeg P. Both IgA subclasses are reduced in parotid saliva from patients with AIDS. Clin Exp Immunol 1991;83:203-9.
24. Sweet SP, Rahman D, Challacombe SJ. IgA subclasses in HIV disease: dichotomy between raised levels in serum and decreased secretion rates in saliva. Immunology 1995;86:556-9.
25. Bergey EJ, Cho MI, Hammarskjold ML, Rekosh D, Levine MJ, Blumberg BM, et al. Aggregation of human immunodeficiency virus type 1 by human salivary secretions. Crit Rev Oral Biol Med 1993;4:467-74.
26. Malamud D, Davis C, Berthold P, Roth E, Friedman H. Human submandibular saliva aggregates HIV. AIDS Res Hum Retroviruses 1993;9:633-7.
27. Shugars DC, Sauls DL, Weinberg JB. Secretory Leukocyte Protease Inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I. Oral Dis 1997;3 Suppl 1:S70-2.
28. Challacombe SJ, Sweet SP. Salivary and mucosal immune responses to HIV and its co-pathogens. Oral Dis 1997;3 Suppl 1:S79-84.
29. Nederfors T, Isaksson R, Mornstad H, Dahlof C. Prevalence of perceived symptoms of dry mouth in an adult Swedish population - relation to age, sex and pharmacotherapy. Community Dent Oral Epidemiol 1997;25:211-6.
30. Cage TW, Pickett FA, editors. Mosby's dental drug reference. St Louis: Mosby-Year Book Inc; 1997. p. 48, 120, 497-8.
31. Meshack AF, Goff DC, Chan W, Ramsey D, Linares A, Reyna R, et al. Comparison of reported symptoms of acute myocardial infarction in Mexican Americans versus non-Hispanic whites (the Corpus Christi Heart Project). Am J Cardiol 1998;82:1329-32.